spacer
home > ebr > autumn 2006 > biotech without borders
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

KITE’S CAR T-CELL THERAPY YESCARTA® (AXICABTAGENE CILOLEUCEL) FIRST IN EUROPE TO RECEIVE POSITIVE CHMP OPINION FOR USE IN SECOND-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA

Stockley Park, UK – 16 September, 2022 – Kite, a Gilead Company, today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, axicabtagene ciloleucel will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement